- Home
- MNOV vs ZTEK Comparison
MNOV vs ZTEK Comparison
Compare MNOV & ZTEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNOV | ZTEK |
|---|---|---|
| Founded | 2000 | 2008 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.4M | 51.8M |
| IPO Year | 2004 | 2022 |
Fundamental Metrics
Financial Performance| Metric | MNOV | ZTEK |
|---|---|---|
| Price | $1.28 | $0.49 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $7.50 | N/A |
| AVG Volume (30 Days) | 41.5K | ★ 137.1K |
| Earning Date | 05-14-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,360,807.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $180.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 194.15 | N/A |
| 52 Week Low | $1.17 | $0.37 |
| 52 Week High | $1.96 | $1.24 |
Technical Indicators
Market Signals| Indicator | MNOV | ZTEK |
|---|---|---|
| Relative Strength Index (RSI) | 43.04 | 50.34 |
| Support Level | $1.21 | $0.46 |
| Resistance Level | $1.32 | $0.56 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 40.00 | 76.95 |
Price Performance
Historical ComparisonAbout MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
About ZTEK Zentek Ltd.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.